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Abstract The concept of immunization was started in
Japan in 1849 when Jenner’s cowpox vaccine seed was
introduced, and the current immunization law was stipu-
lated in 1948. There have been two turning points for
amendments to the immunization law: the compensation
remedy for vaccine-associated adverse events in 1976, and
the concept of private vaccination in 1994. In 1992, the
regional Court of Tokyo, not the Supreme Court, decided
the governmental responsibility on vaccine-associated
adverse events, which caused the stagnation of vaccine
development. In 2010, many universal vaccines became
available as the recommended vaccines, but several vac-
cines, including mumps, zoster, hepatitis B, and rota vac-
cines, are still voluntary vaccines, not universal routine
applications. In this report, immunization strategies and
vaccine development are reviewed for each vaccine item
and future vaccine concerns are discussed.
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Abbreviations
ACIP Advisory Committee on Immunization Practices
BCG Bacillus Calmette–Gue´rin
DTaP Acellular pertussis vaccine combined with
diphtheria and tetanus toxoids
DTwP Whole cell pertussis vaccine combined with
diphtheria and tetanus toxoids
FHA Filamentous hemagglutinin
HA Hemagglutinin
HBV Hepatitis B virus vaccine
Hib Haemophilus influenzae type b conjugated with
tetanus toxoid
HPV Human papilloma virus vaccine
JEV Japanese encephalitis vaccine
IPV Inactivated polio vaccine
LAMP Loop-mediated isothermal amplification
MMR Measles, mumps, and rubella-combined vaccine
MR Measles and rubella-combined vaccine
NA Neuraminidase
NT Neutralization test
OPV Live oral polio vaccine
PCV7 7-valent Streptococcus pneumoniae conjugated
vaccine with recombinant diphtheria toxoid
PT Pertussis toxin
Tdap Tetanus toxoid combined with a reduced
concentration of diphtheria toxoid and
acellular pertussis
VAP Vaccine-associated paralytic polio
VZV Varicella zoster virus vaccine
Dawn of vaccines in Japan
The dawn of vaccinology was the first scientific systematic
investigation of the cowpox vaccination by Edward Jenner
in 1796, although several variations in approach were
performed using dried pus from smallpox skin lesions in
Central Asia, China, and Turkey [1]. Jenner’s cowpox
vaccination procedure was introduced into Japan in the Edo
era by Philipp F.B. von Siebold. Sporadic nationwide
outbreaks occurred at that time, which caused social, eco-
nomic, and political stagnation, and doctors of herbal tra-
ditional medicine, studying Western modern medicine,
wanted to use Jenner’s cowpox vaccine as a preventive
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procedure for smallpox. Many attempts were made to
import the cowpox seed, but these did not succeed because
Jenner’s cowpox vaccine is a live vaccine: it was inacti-
vated during long-term transportation or if the inoculation
chain in children was interrupted. It was finally introduced
to Nagasaki in 1849, bringing the vaccination scar through
the idea proposed by Dr. Souken Narabayashi, who was the
chief doctor of Nabeshima-Han (Saga Prefecture). The
vaccination procedure became available at the Shutousyo
(Vaccination Institute) in Osaka and Edo cities, which was
the origin of the School of Medicine of Osaka and Tokyo
Universities [2]. Jenner’s cowpox vaccine gained in pop-
ularity because of its distinct effectiveness against small-
pox. However, some opinions were against vaccination
because of misunderstanding involving unreasonable and
nonscientific rumors, as has recently been observed.
The Japanese government in the Meiji era decided that all
Japanese people should be immunized with the vaccine for
smallpox, which was stipulated in 1876, and a vaccination
law against smallpox started in 1910. The present immuni-
zation law was implemented in 1948 under occupation by the
United States (US). Issues related to vaccine development
and immunization policies are summarized in Table 1. There
have been two turning points for amendments to the immu-
nization law: the compensation remedy for vaccine-
associated adverse events in 1976, and the concept of private
vaccination in 1994. These two turning points were attrib-
uted to vaccine-associated adverse events or accidents and
lawsuits against serious neurological adverse events after
immunization with vaccinia and the measles, mumps, and
rubella-combined vaccine (MMR) [3]. In 1992, the regional
Court of Tokyo, not the Supreme Court, set the governmental
responsibility for vaccine-associated adverse events because
the government did not make an effort to enlighten the public
and doctors by explaining the possible adverse events asso-
ciated with vaccinations, even though immunization was
recommended to be compulsory [3]. This lack of information
was a major reason why the government was reluctant to take
active immunization strategic action, leading to the so-called
long-term vaccine gap after the discontinuation, in 1993, of
MMR, which had been introduced in 1989, because of the
unexpectedly high incidence of aseptic meningitis caused by
mumps vaccine components [4, 5]. The mechanisms behind
the higher incidence of aseptic meningitis with the combined
live MMR vaccine than with monovalent mumps vaccines
were not clearly identified. Thereafter, new vaccines were
not introduced, but many pediatric vaccines have been
approved in developed countries, with the implementation of
recommended vaccines, which shows that vaccine-prevent-
able diseases should be controlled with available vaccines
Table 1 History of
immunization and vaccine
development in Japan
DPwP Whole cell pertussis
vaccine combined with
diphtheria and tetanus toxoids,
JEV Japanese encephalitis virus
vaccine, MMR Measles, mumps
and rubella-combined vaccine,




type b vaccine, PCV7 7-valent
Str. pneumoniae vaccine, HPV
Human Papilloma virus vaccine
1948: Immunization Law [Smallpox, Diphtheria, Typhoid fever, Salmonella Paratyphi, Pertussis,
Tuberculosis, Typhus, Plague, Cholera, Scarlet fever, Influenza, Leptospirosis]
1951: Preventive law against tuberculosis.
1961: The polio vaccine was recommended.
1962: School immunization with the influenza vaccine Adverse events after the smallpox
vaccination 1968–1970
1968: DPwT was recommended vaccination 1968–1970
1976: Amendment of the immunization law for a compensation
remedy for adverse events: Recommended obligatory
[Smallpox, Diphtheria, Tetanus, Pertussis, Polio];
Temporarily [influenza, JEV]
DPT accidents 1974–1975
1977: The rubella vaccine was recommended.
1978: The measles vaccine was recommended.
1980: Eradication of smallpox and stopped being used.
1981: The mumps vaccine was licensed. MMR scandal 1989–1993
1985: The hepatitis B vaccine was licensed for the prevention of vertical transmission in1986.
1994: Ammendment for private vaccination: Recommended [DPT, Polio, Measles, Rubella, JEV]
Voluntary [influenza, VZV, Mumps]
1995: The hepatitis A vaccine was licensed,
2001: The influenza vaccine was recommended for the elderly [65 years.
2005: BCG was recommended for infants 0–6 months of age. JEV ADEM 2005
2005: The JEV vaccination was interrupted until 2009 and a booster at 14 years was stopped.
2006: The two-dose schedule was started, using the MR combined vaccine.
2009: Pandemic 2009 vaccines were imported from GSK and Novartis.
2010: Hib, PCV7, and HPV were temporarily recommended.
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[6–9]. Haemophilus influenzae type b conjugated with teta-
nus toxoid (Hib) was introduced in 2008, and 7-valent
Streptococcus pneumoniae conjugated vaccine with
recombinant diphtheria toxoid (PCV7) and human papil-
loma virus vaccines (HPV) became available in 2010.
Rotavirus vaccines were introduced in 2012. Several issues
concerning vaccines in Japan are discussed in this article.
Immunization law and schedule
The Japanese immunization law is complicated with dou-
ble-standard categories: routine recommended and volun-
tary vaccination. Routine recommended vaccines consist of
BCG, acellular pertussis vaccine (DTaP), measles and
rubella combined vaccine (MR), inactivated polio (IPV),
Hib, PCV7, HPV, and Japanese encephalitis vaccine (JEV).
Voluntary vaccines are hepatitis B (HBV), mumps, vari-
cella, and rotavirus vaccines. The difference between the
two is the cost of immunization; routine recommended
vaccines are principally covered by the regional govern-
ment [10, 11]. Until 1994, immunization was performed by
mass vaccination in regional Public Health Centers. It was
replaced by private vaccination, derived from the concept
that it is better that vaccinations are performed by chil-
dren’s family doctors who are familiar with their health
conditions. Although this concept was easily accepted by
general physicians, mass vaccination of BCG still contin-
ued in some regions.
In 2010, Hib, PCV7, and HPV began to be used as
temporarily recommended vaccines, and the cost was
partially supported by the regional governments [12].
Vaccination coverage of routine recommended vaccines is
more than 90–95 % for BCG, DTaP, OPV, and MR and
80 % for JEV, whereas that of voluntary vaccines is less
than 30–40 %. During 1990–2000 polyvalent combined
vaccines were developed in the EU and widely used. There
is no licensed polyvalent vaccine in Japan, and the vacci-
nation schedule became much tighter than that in the
1990s, especially in very young infants less than 6 months
of age (Fig. 1). Simultaneous administration of several
vaccines was recommended by the Japanese Pediatric
Association, as has been conducted in the US and EU [3,
4]. In March 2011, seven infants died within a week of
receiving DTaP, Hib, PCV7, or BCG. The newly intro-
duced Hib and PCV7 were temporally discontinued, but
were restarted 1 month later because the risk of serious
adverse events was not higher than that reported in
developed countries. Simultaneous administration has been
safely and effectively performed in the US and EU; how-
ever, the incidence of serious adverse events has been
reported as 0.02–1 in 100,000 [13]. Therefore, simulta-
neous immunization is now performed without a high level
of confidence. Careful surveillance monitoring and
Fig. 1 Immunization schedule. BCG, IPV, DPT, DT, MR, JEV, Hib,
PCV7, and HPV were recommended vaccines and HBV, Mumps,
VZV, and Rota vaccines were voluntary vaccines. Arrows show the
recommended timing for vaccinations. BCG Bacillus Calmette
Gue´rin, IPV Inactivated polio vaccine, DPT Diphtheria and tetanus
toxoids combined with pertussis vaccine, DT Diphtheria and tetanus
toxoids, MR Measles and rubella-combined vaccine, JEV Japanese
encephalitis vaccine, Hib Haemophilus influenzae type b vaccine,
PCV7 7-valent Str. pneumoniae vaccine, HPV Human papilloma
virus vaccine, HBV Hepatitis B virus vaccine, VZV Varicella zoster
virus vaccine
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scientific investigations are required to define the safety of
simultaneous immunization.
Measles and rubella elimination
In Japan, live attenuated measles vaccines were developed
in the 1970s, and four strains were licensed (three strains
are used at present) with the implementation of recom-
mended immunization in 1978 [14]. Five strains of live
attenuated rubella vaccines (three strains are used at pres-
ent) were developed and recommended for female students
aged 14 years in 1977 [15]. Surveillance data and changes
in the vaccination policy against measles and rubella are
shown in Fig. 2. The MMR vaccine was used between
1989 and 1993 but was discontinued in 1993. Measles and
rubella monovalent vaccines have been used for children
aged 12–90 months since 1994 to control measles and
rubella because the number of patients with congenital
rubella syndrome did not decrease as a result of the vac-
cination of only young females since 1977.
Regarding the reporting system for measles in Japan,
through 3,000 sentinel clinics or hospitals for pediatric
infectious diseases and 450 clinics for adult measles surveil-
lance, patients with clinically suspected measles were repor-
ted to Regional Health Care Centers. In the late 1990s to early
2000s, 20,000–30,000 cases of measles, including several
dozen deaths, were reported yearly. A total of 2,034 cases of
Fig. 2 Surveillance results of
measles (a) and rubella (b), and
the changes in immunization
policies. Measles and rubella
vaccines were recommended in
1978 and 1977, respectively.
The MMR vaccine was used
between 1989 and 1993, and the
target generation of the rubella
vaccine shifted from 14-year-
old female schoolchildren to all
infants 12–90 months of age.
The two-dose schedule of the
MR combined vaccine started in
2006. A catch-up campaign
started in 2008 for an additional
5-year schedule for children 13
and 18 years of age. MMR
measles, mumps, and rubella-
combined vaccine
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measles, including 8 deaths, were reported in a severe measles
outbreak in Okinawa in 1998–1999 [16]. Many of the deaths
occurred in infants under 1 year of age. A large measles
outbreak was observed in 2001 in Japan. Among 33,812
reported cases, most patients were under 5 years of age and
had not been vaccinated. Through a vaccination campaign to
increase immunization coverage at 1 year of age, the number
of reported cases decreased to 545 in 2005. The Japanese
Government implemented a two-dose strategy in 2006, a
combined measles and rubella vaccine (MR) for children at 1
and 6 years of age [17]. Therefore, the elimination of measles
was expected. However, patients with measles were increas-
ingly reported in March 2007, and this outbreak subsequently
expanded throughout the Japanese districts, peaking in the
middle of May. Furthermore, several reports indicated mea-
sles transmission by Japanese travelers or participants in an
international sporting event [18–20]. This outbreak showed
different characteristics, demonstrating that most patients
were young adults or adolescents attending high school and
university students, with a much lower proportion of young
infants, at the early stage of the outbreak [21]. Cases of
measles were reported in all age populations, with a total of
3,105 pediatric cases and 959 adult patients being reported in
2007. The number of patients with measles was the highest
between 1 and 4 years of age, accounting for 40–50 % in
2001, which decreased to 22 % in the outbreak of 2007. A
significant shift in the age distribution of cases of measles in
2007 was observed to be 10–14 years or older, accounting for
44 % in 2007 [22].
To reduce the number of patients with measles, an
additional MR catch-up campaign was started for teenagers
at the age of 13 and 18 years (MR III and IV) from 2008
for a 5-year schedule. After 2008, all cases with measles
had to be registered, and the number of patients with
measles was reduced to 457 cases in 2010 (3.58 cases per
million), with some imported genotypes [23]. In 2011,
measles was introduced from the EU by a journalist who
was collecting the news of the earthquake, tsunami, and
nuclear power disaster, and a total of 442 patients with
measles were finally reported [24]. In 2012, 293 patients
were reported, just on the edge of measles elimination of 1
case in 1,000,000, and most cases were identified as
importations from Southeast Asia and the EU [25].
Global measles vaccination coverage increased from
72 % in 2000 to 82 % for the first dose in 2007, and the
two-dose immunization strategy was recommended for
countries with high coverage of the first-dose measles
vaccine, at more than 95 %. Most countries (88 %) now
implement the two-dose strategy [26]. However, measles
transmission has increased, and outbreaks have become
widespread since late 2009 in the EU region because of the
failure to immunize susceptible populations [24]. The
World Health Assembly updated the goal of measles
elimination to a 95 % reduction in measles mortality by
2015, compared to 2000 [27].
The rubella vaccine strategy was markedly changed in
1994. Before 1989, the rubella vaccine was administered to
14-year-old girls, but the vaccine target has changed to all
children aged 12–90 months. Boys more than 90 months of
age and girls from 90 months to 14 years of age were not
enrolled as immunization targets in the transition period.
Even though a temporal catch-up campaign was conducted
to cover the immunization gap, vaccine coverage was
extremely low [15, 28]. According to the immunization gap
in younger generations around 30 years of age, an outbreak
of rubella was observed in 2011–2013, with some imported
cases from Southeast Asia, resulting in congenital rubella
syndrome [29]. Rubella is now prevalent (in 2013) among
men around 30 years of age who have not been immunized
because of the immunization gap. Through the enhanced
network activity of measles and rubella elimination, the
elimination of rubella has been targeted in accordance with
measles elimination, using the measles and rubella com-
bined vaccine [30, 31].
Replacement of oral polio vaccine (OPV)
with inactivated polio vaccine (IPV)
Surveillance data of reported cases of polio paralysis are
shown in Fig. 3. In 1960, a nationwide outbreak was observed,
and approximately 5,800 patients with paralytic polio were
reported. A similar level of outbreak seemed to be observed in
1961, and the Japanese government decided to import suffi-
cient doses of OPV for all Japanese children. Within a month,
15 million doses were given to all Japanese children less than
5 years old. Around 1960, although IPV was under investi-
gation and a clinical trial of imported OPV was also underway
in Japan, the importation of OPV was politically decided.
After the introduction of OPV in 1961 and afterward, the
number of polio cases decreased [32]. After 1980, no wild
strain was isolated from patients suspected of flaccid paralytic
polio. All cases of paralytic polio were identified as vaccine-
associated paralytic polio (VAP). The incidence of VAP was
recently shown to be one in 1.4 million recipients in Japan.
Clinical trials of domestic IPV produced from Sabin’s live oral
polio vaccine strains were performed beginning in 1998, but
the application was withdrawn. Considering the practical way
of immunization, the development of IPV combined with
DTaP was more desirable than IPV alone. OPV was replaced
with IPV in most developed countries, but it was delayed by
the standstill of the IPV trial in Japan. Some guardians and
pediatricians could not wait for the licensure of domestic
DTaP/IPV and imported the IPV vaccine privately at their
own responsibility. In 2012, IPV was allowed for use as a
recommended vaccine imported from Sanofi and domestic
J Infect Chemother (2013) 19:787–798 791
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DTaP/IPV vaccines [33]. The wild poliovirus was imported in
several situations from countries where wild polio has been
circulating, and the high levels of vaccine coverage have been
maintained. In addition to disease surveillance, environment
surveillance of the vaccine for polio virus should focus on
sewage monitoring [34].
Is the DTaP vaccine effective in controlling pertussis?
Pertussis is still a serious illness in young infants, and
causes whooping cough, apnea, cyanosis, choking, and
encephalopathy [35]. In Japan, the whole-cell pertussis
vaccine was developed in 1949 and was combined with
diphtheria and tetanus toxoids (DTwP). The results of
pertussis surveillance and changes in vaccine strategy are
shown in Fig. 4. Although febrile adverse illness was
observed in 10 % of the recipients of DTwP, with local
reactions of redness at 50–60 % and induration at 20 %,
this vaccine was accepted. A routine immunization sche-
dule was implemented with DTwP in 1968, resulting in a
reduction in the reported cases of pertussis and pertussis
deaths. In 1974–1975, two accidental deaths were reported
after the administration of DTwP and, thereafter, DTwP
Fig. 3 Polio surveillance in
Japan since 1950. A peak
number of patients with polio
was observed in 1960, and the
live polio vaccine was
introduced in 1961 (upper
panel). After 1962, the number
of patients with polio decreased,
and no wild strain has been
isolated since 1980
Fig. 4 History of the pertussis
vaccine and surveillance of the
number of reported cases of
pertussis and pertussis deaths.
The DPT vaccine was
recommend in 1968. P Pertussis
vaccine, DP Diphtheria toxoid
combined with pertussis
vaccine, DPT Diphtheria and
tetanus toxoids combined with
pertussis vaccine, DTaP
acellular pertussis vaccine
combined with diphtheria and
tetanus toxoids
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was temporarily discontinued. It was reintroduced for
children aged 2 years old and older, or the DT vaccine was
used instead of DTwP. The number of pertussis patients
and pertussis deaths increased because of the low vaccine
coverage [36, 37].
In 1981, a new type of acellular pertussis was devel-
oped, and a combined vaccine (DTaP) was introduced into
recommended immunization practice. Principally, two
types of DTaP vaccine (Biken-type, B-type; Takeda-type,
T-type) were developed: the B-type consisted of two major
antigens, pertussis toxin (PT) and filamentous hemagglu-
tinin (FHA), and the T-type contained pertactin and fimb-
riae in addition to PT and FHA [38, 39]. Nationwide
monitoring of clinical adverse events demonstrated low
reactogenicity and sufficient antibody responses similar to
natural infection. Since 1981, the number of pertussis
patients has decreased after the acceptance of DTaP.
However, the incidence of pertussis has recently been
increasing in adults since 2002 in Japan, and several out-
breaks on university campuses and in high schools and
offices have been reported [40, 41]. Adult patients of per-
tussis are difficult to diagnose because of nontypical clin-
ical features, including a prolonged cough. Also, the
isolation of Bordetella or detection of the pertussis genome
is not always successful because of the short duration of
excretion of Bordetella influenced by the empirical
administration of antibiotics or vaccination history [41,
42]. A surveillance system is currently under construction
in Japan, based on a genetic diagnosis by loop-mediated
isothermal amplification (LAMP) for detection of the per-
tussis genome [43].
DTaP was adopted by global vaccine makers because of
the lower incidence of adverse events than that with DTwP,
and multivalent combined vaccines, such as DTaP/Hib/
IPV/HBV hexavalent vaccines, were developed based on
DTaP. Pertussis is principally an infectious children’s ill-
ness causing whooping and prolonged cough, and the
Advisory Committee on Immunization Practices (ACIP)
recommended a five-dose DTaP schedule, at ages 2, 4, 6,
15–18 months, and 4–6 years, instead of the previous
DTwP in the US in 1997 [44]. In the 1990s, the incidence
of pertussis at an older age increased in many countries
because of waning immunity after primary childhood
immunization and antigenic changes in pertussis, and
adolescent pertussis was identified as the source of the
transmission of pertussis to young infants through
enhanced surveillance studies [45]. In Japan, the number of
newborn pertussis cases increased in household contact
[46]. In 2005, the tetanus toxoid, combined with a reduced
concentration of diphtheria toxoid and acellular pertussis
components (Tdap) vaccine, was licensed in the US, and
the ACIP recommended that adolescents aged 11–18 years
old should receive a single dose of Tdap for a booster
immunization [47]. It is now recommended for all gener-
ations from 19 to more than 64 years of age who have not
been vaccinated in the past 10 years [48]. In Japan, DT was
recommended at the age of 11–12 years, and the lack of
pertussis booster immunization is one of the reasons why
the number of patients with pertussis has increased in
adults. The booster effect of a reduced volume of DTaP
was investigated instead of the DT vaccine at 11–12 years
of age, and 0.2 ml DTaP induced sufficient antibodies
against PT and FHA without serious adverse events [49].
Even with high vaccine coverage, the number of pertussis
patients increased globally because of the short duration of
vaccine immunity. Several DTaP candidates containing
additional protective antigen(s) are now under investiga-
tion [50].
Does the influenza split vaccine prevent infection?
Two types of influenza virus vaccines are now globally
available, inactivated and cold-adapted live attenuated
vaccines. There are three types of inactivated vaccines:
whole virion, split, and subunit inactivated vaccines. The
whole virion inactivated vaccine induced febrile reactions
after the vaccination, and thereafter the split vaccine was
licensed in 1972 in Japan, which has been used for more
than 40 years with a lower incidence of febrile reactions.
The split vaccine is made by destroying the structure of
virus using detergents and ether to remove their lipid
components from the formalin-inactivated whole virion.
The HA subunit vaccine is purified from the HA fragments
zone [51]. Changes in immunization policies, vaccine
production, and the population aged less than 15 and more
than 65 years are shown in Fig. 5. The transmission of
influenza was believed to be associated with contact with
schoolchildren, and, thereafter, the influenza vaccine has
been recommended every year as school immunization in
primary schools since 1962 [52]. In the 1960s, the pediatric
population (\15 years of age) was more than 20 million,
and more than 25 million doses of influenza vaccine were
produced. The effects of school immunization on
decreasing the social impact of influenza were question-
able, and a comparative study was performed. There was
no difference in the number of reported cases, number of
hospital visits, and cost of healthcare insurance among
several cities with or without school immunization in
Gunma Prefecture in the early 1980s. This study provided
evidence that school immunization had no effect on
reducing the impact of influenza in the community, but had
a limited effect on an individual basis [53, 54]. The influ-
enza vaccine strategy was shifted from an obligatory rou-
tine vaccine to a voluntary vaccine in 1994. School
immunization was interrupted in 1995, and the total
J Infect Chemother (2013) 19:787–798 793
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amount of vaccine produced was at its lowest, 0.35 million
doses. A large outbreak of H3N2 was observed in 1997,
and several deaths were reported in many nursing homes
for the elderly as social topics. It has been recommended as
a routine recommended vaccine for the elderly more than
65 years of age since 2002 for the benefits of vaccine
recipients [55].
Three pandemics of influenza occurred in the 20th
century. The most devastating pandemic dated back to
1918 and was known as Spanish flu. It was caused by a
highly pathogenic H1N1 influenza virus transmitted
through some animals from an avian pathogenic virus and
is estimated to have killed 40–50 million people [56]. In
1957, Asian influenza A/H2N2 caused the second pan-
demic, and Hong Kong influenza A/H3N2 appeared as the
third pandemic in 1968. Seasonal influenza outbreaks or
epidemics are caused by an antigenic drift of A/H1N1 or
A/H3N2, whereas these pandemics appeared as an anti-
genic shift, leading to a new strain, which is thought to be a
re-assortment with the non-preexisting features of hemag-
glutinin (HA) or neuraminidase (NA) in human influenza
viruses. After the 1968 pandemic of A/H3N2, several cases
and small local outbreaks were reported, caused by new
strains, H5, H7, or H9, and were considered to be from
poultry, with H5 being very close to humans as a target for
vaccine development [57]. A regional outbreak of H5 was
reported in Hong Kong in 1997, and 6 of 18 patients died,
causing an H5 pandemic threat [58]. Sporadic H5 trans-
mission on poultry farms and in migratory birds has spread
across Asia to the EU and Africa, and approximately 610
cases of human H5 infection have been reported at present
in 2013 since 2003, showing a high mortality rate of
approximately 60 %. Most cases have involved close and
direct contact with poultry, with no definite evidence of
human-to-human transmission. There are several barriers
to human-to-human transmission: receptor usage of the HA
protein, cleavage efficiency by cellular protease, and host
factors. H5N1 is considered to be a target for the pandemic
vaccine, and the WHO addressed sharing viruses and
sequence information for a future pandemic vaccine
development [57, 59]. The development of an effective and
safe vaccine is expected to mitigate the threat of a
pandemic.
Several types of H5 vaccines have been developed,
basically based upon the HA split, subunit vaccine, or
whole virion inactivated with adjuvant. In Japan, alum-
adjuvanted H5N1 whole virion inactivated vaccine (WIV)
(alum concentration, 300 lg/ml) was developed using a
genetically engineered reassortant, the NIBRG-14 strain,
originating from H5N1/A/Vietnam/1194/2004. In a clinical
phase II/III trial in healthy adults, alum-adjuvanted WIV
(HA protein, 15 lg) led to favorable immunogenic-
ity, [70 % sero-conversion rate in neutralization tests
(NT) antibodies, without causing any serious systemic ill-
nesses [60]. However, when it was administered to young
infants and children at a reduced dose, 7.5 or 3 lg, a high
body temperature (C38.0 C) was observed in approxi-
mately 60 % of recipients less than 7 years of age, and,
unexpectedly, NT antibody titers were higher in children
than in the clinical trial in adults. These phenomena were
associated with the enhanced production of inflammatory
cytokines [61].
Fig. 5 Changes in the
immunization strategy of the
influenza vaccine,
population more than 65 years
and less than 15 years of age,
and vaccine production in
million doses
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Introduction of Hib, PCV7, and HPV
Hib and PCV are the major pathogens of bacterial men-
ingitis and invasive systemic bacteremia, and they cause
serious pneumonia. In the past, bacterial infection was
believed to be treatable with antibiotics through early
diagnosis and was not a target for vaccine development
before 2000 in Japan. However, a shift led to the devel-
opment of vaccines in the late 1980s in the US. The
appearance of resistant strains provided an impetus for the
introduction of vaccines. In Japan, the surveillance study of
the incidence of Hib meningitis was conducted, which
showed the incidence was 8.3 per 100,000 children less
than 5 years of age [62, 63]. These surveillance results
estimated 600 cases of serious invasive Hib infection, and
then, the Hib vaccine was introduced. In the postmarketing
study, the practical usage of Hib simultaneously adminis-
tered with DPT was confirmed to be safe and effective,
similar to separate administration [64]. It was allowed in
2008, and Hib was the first vaccine imported from a foreign
country. Thereafter, PCV7, HPV, and Rota vaccines were
licensed. Hib, PCV7, and HPV vaccines were temporarily
adopted as routine recommended vaccines in 2010 with
tentative financial support and were engaged to be covered
as routine recommended vaccines in 2013 [10]. After the
introduction of Hib and PCV7, the incidence of serious
invasive infection decreased whereas the Streptococcus
pneumoniae 6B and 19A serotypes uncovered by PCV7 are
increasing, with a higher number of penicillin-resistant
strains [65, 66]. Hib infection became controlled but S.
pneumoniae has approximately 100 serotypes, using sero-
type replacement after the introduction of PCV7 and
PCV13 to be licensed.
Action for the routine immunization of mumps, zoster,
and hepatitis B vaccines
Five live mumps vaccine strains were developed in the
1970s from domestic wild strains isolated in the 1960s and
1970s [67, 68]. MMR vaccines containing four domestic
vaccine strains were used, but were discontinued because
of the unexpected high incidence of aseptic meningitis.
Thereafter, monovalent mumps vaccines were used and the
incidence of aseptic meningitis was evaluated. We reported
that the incidence of aseptic meningitis was 13/1,051
(1.24 %) in patients with symptomatic natural mumps
infection and was estimated to be 0.7–1.1 % of overall
infections considering asymptomatic infections, and
10/21,465 (0.05 %) in vaccine recipients [69]. Although
aseptic meningitis is considered to be an apparent adverse
event of the mumps vaccine, its incidence is considerably
lower than among those with symptomatic natural
infections. It provides informative findings for consider-
ation of resuming the mumps vaccine as a part of a routine
immunization schedule for Japanese children. Regarding
mumps deafness, the incidence of deafness was previously
believed to be 1 in 15,000 [70], but irreversible mumps
deafness occurred at a higher incidence, in 1 case per 1,000
[71]. Mumps deafness is one of the targets for vaccine
implementation. Mumps outbreaks were observed every
3–5 years because of low vaccine coverage, less than
40 %, because the vaccine was voluntary.
The varicella zoster virus vaccine OKA strain was
developed in Japan in 1974, and is the only strain available
in the world [72]. Initially, it was developed for immuno-
compromised hosts who develop serious complications
with chickenpox [73]. It causes no serious adverse reaction
and protects against the onset of illness by immediate
inoculation within 3 days of contact with patients in
pediatric wards [74]. It was allowed for use in healthy
infants, but the yearly epidemiological pattern did not
change because of the low vaccine coverage, less than
40 % [75].
Mumps and zoster vaccines were universal vaccines in
the US and EU but were voluntary in Japan [10, 12, 75].
The hepatitis B vaccine (HBV) is still a voluntary vaccine,
as HBV was developed to interrupt the carrier through
vertical transmission from carrier mothers positive for the
HBe antigen [76]. HBV was given at 2, 3, and 5 months of
age, and the number of carriers became markedly reduced.
Recently, cases of nosocomial infections or horizontal
transmission cannot be neglected, and HBV should be
adopted as a universal vaccination [77]. Mumps, zoster,
and HBV are still voluntary vaccines in Japan although
they are globally recommended as universal vaccines.
These vaccines are anticipated to be routine recommended
vaccines.
Requirement for future immunization
The disease surveillance system in Japan is based on 3,000
sentinel clinics or hospitals for pediatric infectious diseases
and reflects the tendency of infectious diseases, not popu-
lation-based incidences. The immunization strategy is
decided based upon disease surveillance, and monitoring of
vaccine-associated adverse events is important to assess the
safety. It is now based on postmarketing surveillance in
Japan and should be developed in a systematic adminis-
trative form, together with laboratory investigations. It is
difficult to identify the relationship of vaccination to seri-
ous adverse events occurring within a few weeks after
immunization, and, in most cases, a direct relationship
could not be identified. In 2005, a serious case of acute
disseminated encephalomyelitis (ADEM) was reported
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after vaccination with the Japanese encephalitis vaccine
(JEV). At that time, JEV was produced from purified virus
particles from mouse brains infected with Japanese
encephalitis virus. Therefore, JEV has the potential to
cause allergic encephalomyelitis. JEV was suddenly dis-
continued in a shortsighted political decision, without
considering the effects of blank periods without JEV. At
that time, tissue-culture JEV was ready to be marketed.
Comprehensive decisions are required and should be made
after scientific discussion.
No organization for decision making on immunization is
currently systematized in Japan, such as the Advisory
Committee on Immunization Practices (ACIP) of the US
[12]. An investigational Committee on Immunization was
organized to propose immunization strategies to decision
makers and to discuss problematic issues based on the
scientific evidence. However, this committee has been
organized in the administrative agency, the Ministry of
Health, Labor, and Welfare. Although issues on immuni-
zation should be discussed based on scientific evidence as a
third party, it belongs to the political side at present. It may
be hard to listen to the clinical needs of general physicians
for the improvement of immunization practice. It should be
organized for the purpose of promoting public health with a
longitudinal vision for immunization policies and prompt
responses to the critical issues, without the influence by
political changes.
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